LTR Pharma Ltd (ASX: LTP) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
LTR Pharma Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$94.05 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
180.98 million
Earnings per share
-0.050
Dividend per share
N/A
Year To Date Return
143.48%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
LTR Pharma Ltd (ASX: LTP)
Latest News
No posts found.
LTP ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About LTR Pharma Ltd
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
LTP Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Dec 2024 | $0.84 | $-0.01 | -1.18% | 462,664 | $0.87 | $0.88 | $0.84 |
| 19 Dec 2024 | $0.85 | $0.01 | 1.19% | 736,536 | $0.84 | $0.86 | $0.80 |
| 18 Dec 2024 | $0.84 | $0.03 | 3.68% | 784,466 | $0.82 | $0.86 | $0.80 |
| 17 Dec 2024 | $0.82 | $-0.05 | -5.81% | 962,415 | $0.86 | $0.87 | $0.81 |
| 16 Dec 2024 | $0.86 | $0.00 | 0.00% | 2,851,316 | $0.86 | $0.90 | $0.84 |
| 13 Dec 2024 | $0.86 | $-0.04 | -4.47% | 1,334,882 | $0.90 | $0.90 | $0.84 |
| 12 Dec 2024 | $0.90 | $-0.04 | -4.30% | 1,305,807 | $0.96 | $0.97 | $0.88 |
| 11 Dec 2024 | $0.93 | $-0.05 | -5.10% | 771,760 | $0.98 | $0.98 | $0.93 |
| 10 Dec 2024 | $0.98 | $-0.07 | -6.67% | 1,273,280 | $0.99 | $1.03 | $0.96 |
| 05 Dec 2024 | $1.05 | $-0.03 | -2.78% | 484,194 | $1.10 | $1.12 | $1.04 |
| 04 Dec 2024 | $1.08 | $-0.09 | -7.69% | 701,178 | $1.19 | $1.19 | $1.08 |
| 03 Dec 2024 | $1.17 | $-0.02 | -1.69% | 288,983 | $1.19 | $1.19 | $1.17 |
| 02 Dec 2024 | $1.19 | $-0.08 | -6.35% | 556,029 | $1.26 | $1.28 | $1.19 |
| 29 Nov 2024 | $1.26 | $0.03 | 2.44% | 184,685 | $1.25 | $1.28 | $1.19 |
| 28 Nov 2024 | $1.23 | $-0.02 | -1.60% | 201,955 | $1.25 | $1.25 | $1.21 |
| 27 Nov 2024 | $1.25 | $0.05 | 4.18% | 272,779 | $1.20 | $1.25 | $1.17 |
| 26 Nov 2024 | $1.20 | $-0.01 | -0.83% | 441,329 | $1.23 | $1.24 | $1.19 |
| 25 Nov 2024 | $1.21 | $-0.01 | -0.82% | 294,020 | $1.23 | $1.26 | $1.21 |
| 22 Nov 2024 | $1.22 | $-0.01 | -0.82% | 285,372 | $1.25 | $1.26 | $1.21 |
| 21 Nov 2024 | $1.23 | $0.01 | 0.82% | 335,700 | $1.22 | $1.27 | $1.21 |
| 20 Nov 2024 | $1.22 | $-0.03 | -2.40% | 470,923 | $1.25 | $1.26 | $1.20 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 02 Dec 2024 | Maja McGuire | Issued | 100,000 | $118,500 |
Issue of options.
|
| 02 Dec 2024 | Julian Chick | Issued | 100,000 | $118,500 |
Issue of options.
|
| 02 Dec 2024 | Lee Rodne | Issued | 100,000 | $118,500 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Julian John Chick | Non-Executive Director | Nov 2020 |
Dr Chick is an experienced healthcare executive with over 20 years of experience in senior management and board positions including in ASX listed companies Avexa and Admedus. He has 8 years of investment banking experience and has also held a role as an analyst reviewing healthcare and biotechnology investment opportunities for private equity investors and venture capitalists.
|
| Mr Lee Rodne | Executive ChairmanExecutive Director | Oct 2020 |
Mr Rodne holds over 25 years of experience in the healthcare and technology sectors and has been in executive leadership roles in both Public and Private enterprises.
|
| Ms Maja Aleksandra McGuire | Non-Executive Director | Sep 2021 |
Ms McGuire is an experienced corporate executive and company director, bringing over 15 years of experience at board and senior management level. This includes working with listed companies as a non-executive chair/director, general counsel and in top tier legal private practice. She is Chair of the Risk Committee.
|
| Mr Shelby Coleman | Company Secretary | Dec 2024 |
-
|
| Shelby Coleman | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| LTR Medical Pty Ltd | 46,373,750 | 30.13% |
| Strategic Drug Solutions Inc | 5,933,000 | 3.86% |
| Trexapharm Inc | 4,188,000 | 2.72% |
| Citicorp Nominees Pty Limited | 4,143,610 | 2.69% |
| Go Medical Industries Pty Ltd | 2,443,000 | 1.59% |
| Mr Peter James Hendry | 1,815,000 | 1.18% |
| Wolseley Road No. 1 Pty Limited | 1,747,500 | 1.14% |
| Parkview Sc Bio Llc | 1,500,000 | 0.97% |
| Mr Philip John Cawood | 1,420,179 | 0.92% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 1,329,377 | 0.86% |
| UBS Nominees Pty Ltd | 1,300,000 | 0.84% |
| Gleneagle Securities Nominees Pty Limited | 1,225,000 | 0.80% |
| SSRA Pty Limited <Scully Family A/C> | 1,161,000 | 0.75% |
| Fredronn Pty Ltd <Fredronn Family A/C> | 1,144,250 | 0.74% |
| Danny Zanardo | 1,122,135 | 0.73% |
| Mr Peter Wade <Wade Family A/C> | 1,034,081 | 0.67% |
| LTR Consulting Pty Ltd | 982,143 | 0.64% |
| Chifley Portfolios Pty Limited <David Hannon A/C> | 970,000 | 0.63% |
| Tempest Dawn Pty Limited <Swt Super Fund A/C> | 960,000 | 0.62% |
| Mr Moghseen Jadwat | 957,500 | 0.62% |
